Resistance-proof drugs

Over the past few decades research has shown that infections are not only crucially dependent on the gene functions of the pathogen but also those of its host, e.g. humans. This realization has opened up a new treatment approach termed "host-directed infection therapy", which is currently receiving increased levels of interest in the area of infection medicine. Our researchers at the Max Planck Institute have been instrumental in shaping this new approach, which promises to be highly resilient to the development of resistance by rapidly adapting bacteria and viruses. These new, host-directed pharmaceuticals could close an important gap in the treatment of infectious diseases.

Research in this new field is making rapid progress, supported to a large part by the partners of the Foundation. In this way, highly effective "host-directed" compounds have already been identified for the three pathogens targeted so far: influenza and chikungunya viruses, as well as Chlamydia. They are currently undergoing preclinical trials. Based on these promising successes, we are now putting intense efforts into finding an effective drug against Ebola. Another focus of our current plans is the increasingly important problem of multi-resistant bacteria.